
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $281.2B · as of 2026-06-23
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| Lonafarnib | Phase 2 | Breast Cancer |
| MK1903 | Phase 2 | Dyslipidemia |
| Elbasvir | Phase 3 | Hepatitis C |
| denufosol tetrasodium Inhalation Solution | Phase 2 | Cystic Fibrosis |
| CXA-101 | Phase 2 | Complicated Urinary Tract Infection |
| V260 | Phase 3 | Rotavirus Gastroenteritis |
| Vericiguat tablet | Phase 3 | Heart Failure |
| MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks | Phase 2 | Hypercholesterolemia |
| pegylated interferon | Phase 2 | Chronic Hepatitis C |
| Pegylated interferon alfa-2b (SCH 54031) | Phase 3 | Hepatitis C, Chronic |
| MK-8591A | Phase 3 | HIV-1 Infection |
| Multiple low dose cyclophosphamide | Phase 2 | Multiple Myeloma |
| Prevenar 13™ | Phase 3 | Pneumococcal Infections |
| Imipenem | Phase 3 | Bacterial Pneumonia |
| RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent | Phase 3 | Vomiting |
| Zanzalintinib | Phase 3 | Renal Cell Carcinoma |
| denufosol tetrasodium (INS37217) | Phase 2 | Cystic Fibrosis |
| OPT-80 | Phase 2 | Diarrhea |
| methotrexate | Phase 3 | Psoriasis |
| 5-FU | Phase 3 | Metastatic Esophageal Squamous Cell Carcinoma |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.
See ProData from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.